Bluebird’s Latest Gene Therapy Stumble Will Help Vertex Close The Gap
Gene Therapy Launch Delayed Again
Once the darling of biotech investors, Bluebird Bio’s go-it-alone strategy with Zynteglo has not paid off as German launch plans stall.
You may also be interested in...
The cost-effectiveness watchdog now assumes an upfront $2.1m payment instead of five annual payments. The company switched gears to the US after the TDT gene therapy stumbled in Europe.
The firm is laying off a big piece of its workforce and deprioritizing some investments to free up capital for potential upcoming launches, but that could add commercial risks.
Its Q4 earnings report was not the first time that bluebird mentioned selling priority review vouchers it has not received yet, but the PRV revenue is needed to fund operations beyond 2022.